Eli Lilly and Company (NYSE:LLY) Position Lowered by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. reduced its position in Eli Lilly and Company (NYSE:LLY) by 6.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 108,441 shares of the company’s stock after selling 7,638 shares during the quarter. Eli Lilly and Company makes up about 1.0% of Cullen Frost Bankers Inc.’s investment portfolio, making the stock its 25th biggest holding. Cullen Frost Bankers Inc.’s holdings in Eli Lilly and Company were worth $63,212,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $26,000. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company in the third quarter worth about $27,000. Optiver Holding B.V. bought a new position in Eli Lilly and Company in the third quarter worth about $36,000. Family CFO Inc acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $40,000. Finally, O Brien Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 70.5% during the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock traded up $11.09 during mid-day trading on Tuesday, hitting $777.77. 2,842,407 shares of the stock traded hands, compared to its average volume of 3,088,457. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The company’s 50-day simple moving average is $761.22 and its 200-day simple moving average is $674.88. The firm has a market cap of $739.20 billion, a price-to-earnings ratio of 114.55, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.62 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Citigroup raised their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.